Blog
RSS FeedPosted by Michael Wonder on 01 Dec 2022
Takeda Korea's Kynteles SC wins insurance benefit
1 December 2022 - Takeda Pharmaceuticals Korea said Kynteles SC, an inflammatory bowel disease treatment, started to be covered by ...
Posted by Michael Wonder on 28 Nov 2022
'Reimbursement criteria for CGRP inhibiting migraine drugs not realistic'
28 November 2022 - The CGRP (calcitonin gene-related peptide) inhibitors, developed to prevent adult migraines, have recently been registered on ...
Posted by Michael Wonder on 27 Oct 2022
MSD's Zerbaxa becomes Korea's newest antibiotic to receive reimbursement
27 October 2022 - MSD Korea is strengthening its position in the local antibiotic market with Zerbaxa (ingredient: ceftolozane/tazobactam) after ...
Posted by Michael Wonder on 12 Oct 2022
‘Current standard for stopping insurance benefits for SMA treatment harsh on adult patients’
12 October 2022 - Spinraza (nusinersen sodium), the first spinal muscular atrophy treatment that won the insurance coverage quickly since ...
Posted by Michael Wonder on 26 Sep 2022
Janssen's Imbruvica passes reimbursement review, BeiGene's Brukinsa fails
22 September 2022 - Janssen's Imbruvica (ibrutinib) and BeiGene's Brukinsa (zanubrutinib), the two BTK (Bruton tyrosine kinase) inhibitors with the ...
Posted by Michael Wonder on 11 Sep 2022
Health movement in South Korea fights for universal access to medicines
10 September 2022 - Civil society in South Korea renewed its commitment to ensure universal access to medicines and public pharmaceutical ...
Posted by Michael Wonder on 01 Sep 2022
Janssen's Stelara gets insurance benefits as first-line therapy for ulcerative colitis
1 September 2022 - Janssen Korea said its ulcerative colitis Stelara (ustekinumab) won health insurance benefits as the primary treatment ...
Posted by Michael Wonder on 11 Aug 2022
Amgen's acute lymphoblastic leukaemia drug Blincyto passes reimbursement review
11 August 2022 - Amgen's acute lymphoblastic leukaemia treatment Blincyto (blinatumomab) passed the reimbursement review about two years after expanding ...
Posted by Michael Wonder on 02 Aug 2022
Delay of Evrysdi reimbursement review denies SMA patients' right to drug choice
2 August 2022 - The Government has been dragging its feet to review insurance benefits for Roche's new spinal muscular ...
Posted by Michael Wonder on 02 Aug 2022
Korea's first gene treatment for SMA Zolgensma gets insurance benefits
2 August 2022 - Novartis Korea said Monday that it released Zolgensma, the nation's first gene replacement treatment for spinal ...
Posted by Michael Wonder on 21 Jul 2022
Ultra-expensive SMA drug Zolgensma to get insurance benefits from August
21 July 2022 - Novartis' Zolgensma (onasemnogene abeparvovec), the world's most expensive drug yet to treat spinal muscular atrophy, will ...
Posted by Michael Wonder on 17 Jul 2022
'Government excessively controls drug prices, not recognising novel drugs' value'
15 July 2022 - The Government is wielding excessive power to lower drug prices without recognising the values of innovative ...
Posted by Michael Wonder on 10 Jul 2022
Celltrion Pharm's liver disease drug may lose insurance benefits
8 July 2022 - Celltrion's prescription liver disease treatment Godex might lose reimbursement because the HIRA recently decided to withdraw ...
Posted by Michael Wonder on 30 Jun 2022
Revlimid maintenance therapy passes reimbursement review
30 June 2022 - Revlimid maintenance therapy to treat multiple myeloma passed the health insurance review agency’s reimbursement review four ...
Posted by Michael Wonder on 29 Jun 2022
Reimbursement price of GERD drug Fexclu finalised at $0.73
29 June 2022 - The Ministry of Health and Welfare’s health insurance policy committee set the reimbursement price of Fexclu ...